BioStem Technologies receives patent approvals for placental allografts

BioStem Technologies announced that the United States Patent and Trademark Office issued Notices of Allowance for four divisional U.S. design patent applications related to fenestrated human placental allograft technologies. The European Patent Office also granted the company a patent covering sterile human placental allografts and manufacturing methods.

The four U.S. design patents (Nos. 30/010,024, 30/010,026, 30/010,032, and 30/010,034) cover different fenestrated human placental allograft designs intended for wound care and surgical applications. The designs focus on fluid management, conformability, and tissue integration characteristics.

The European patent (EP4442316A2) covers sterile human placental allografts and processing methods designed to preserve structural integrity and growth factors in placental tissue. The technology uses cleaning, low-temperature dehydration, and low-dose e-beam sterilization techniques for applications in wound healing, dental, cosmetic and surgical procedures.

"This milestone reflects our continued focus on protecting the innovation behind our advanced perinatal tissue allograft technologies," said Jason Matuszewski, Chief Executive Officer of BioStem Technologies. "Our growing intellectual property portfolio supports our mission to deliver leading-edge solutions to clinicians and their patients."

The company stated these patents add to its portfolio of more than 70 patents. BioStem Technologies develops and commercializes placental-derived biologics for regenerative medicine applications.

The information is based on a company press release.

You May Also Be Interested In

• Portillo's names Christopher Hansen executive chef and culinary head
• Nexstar completes ATSC 3.0 rollout in Cleveland, final major U.S. market
• Kinetic expands fiber network in Lexington, S.C. by 23%